Danish HMO manufacturer up for sale
Danish biotech company Glycom A/S, which produces Human Milk Oligosaccharides (HMO) for infant formula, would be up for sale at the end of the year as its founders are seeking liquidity in the investment, Glycom CEO Odd Erik Hansen said on Wednesday.
"Some journalists have picked up the story, so there is no point denying it," Hansen told Xinhua.
Investors were attracted by Glycom's performance in the infant formula market place.
Meantime, Glycom is also providing the HMO ingredient for use in the treatment of irritable bowel syndrome suffered by around 12 percent adults worldwide, Hansen added.
The potential sale has already attracted some major prospective buyers including a number of capital funds and two listed companies: the Danish ingredient giant Chr. Hansen and its Dutch competitor DSM, according to the Danish financial newspaper Borsen.
The HMO ingredient is the third largest component of breast milk which was unavailable for manufactured infant formula until Glycom started producing it. Currently, the HMO ingredient has been used in 55 markets across the world.